Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news


From To
Access: MSF reports on use of the new tuberculosis drugs bedaquiline and delamanid

Access to the new tuberculosis (TB) drugs remains severely limited worldwide, but MSF hopes its experience can inform and encourage wider use, while needed clinical research continues.

26 October 2016
Médecins Sans Frontières (MSF) International
Global pledge to stamp out drug-resistant infections

The 193 countries of the United Nations sign a landmark declaration to rid the world of drug-resistant infections or superbugs.

21 September 2016
BBC Health
Without Success in India, We'll Never Control Drug-Resistant Tuberculosis Anywhere

Two newly released studies from India make the global fight against antibiotic resistance and drug-resistant tuberculosis (TB) feel even more daunting. India is critical to the control of TB and other antibiotic resistance, as it is both the largest consumer of antibiotics in the world and has the highest burden of TB, affecting 2.2 million of its people each year, a quarter of the world total.

01 September 2016
HIV is not a super-spreader of drug-resistant tuberculosis

While the human immunodeficiency virus (HIV) pandemic fuels tuberculosis (TB) outbreaks, it does not drive the development and transmission of multidrug-resistance in TB patients as previously suspected, according to a study published in eLife.

09 August 2016
EurekAlert (press release)
Shortened regimen for MDR-TB shows good results for children

The use of the shortened 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB), known as the ‘Bangladesh regimen’ has shown to be successful in 83% of children and adolescents

18 July 2016
Lesley Odendal
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen

These FAQs address key points regarding the implementation of the WHO treatment guidelines for drug-resistant tuberculosis, 2016 update, in TB and TB/HIV programmes.

15 June 2016
World Health Organization
The Worst Superbug? Tuberculosis

The ground-breaking publication of Lord Jim O'Neill's global Review on Antimicrobial Resistance (AMR) is the wake-up call the world desperately needs. Have no doubts: the 'superbugs' that develop antimicrobial resistance are a threat of immense proportions and have a potential impact of 10 million deaths a year by 2050 as antibiotic efficacy dwindles.

20 May 2016
Huffington Post UK
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients

New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.

12 May 2016
World Health Organization
STREAM clinical study first to include bedaquiline to test shortened treatment regimens for multidrug-resistant III in Phase III trial

Stage 2 of the trial aims to reduce MDR-TB treatment from 24 months to 6 or 9 months.

18 April 2016
International Union Against Tuberculosis and Lung Disease
Battling TB and other outbreaks “staff, stuff, space, and systems ” still lacking

Paul Farmer first saw multidrug-resistant tuberculosis in the early 1990s in Haiti, from where he smuggled a patient’s sputum sample to test for drug resistance in Boston. Months later, Partners in Health co-founder Dr. Jim Kim with other colleagues discovered a cluster of fifty MDR-TB patients in a squatter settlement of 100,000 in Lima, Peru. That’s when they started to talk to the world about the emergence of MDR-TB.

24 March 2016
Science Speaks

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.